Aerie Pharmaceuticals market cap is $625.1 m, and annual revenue was $83.14 m in FY 2020

Aerie Pharmaceuticals Gross profit (Q1, 2021)16.3 M

Aerie Pharmaceuticals Gross profit margin (Q1, 2021), %70.8%

Aerie Pharmaceuticals Net income (Q1, 2021)-42 M

Aerie Pharmaceuticals EBIT (Q1, 2021)-34.2 M

Aerie Pharmaceuticals Cash, 31-Mar-2021122.7 M

Aerie Pharmaceuticals EV732.4 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|

## Revenue | 24.2m | 69.9m | 83.1m | |||||

## Cost of goods sold | 641.0k | 22.8m | 25.3m | |||||

## Gross profit | 23.5m | 47.1m | 57.8m | |||||

| 97% | 67% | 70% | |||||

## R&D expense | 72.1m | 86.1m | 91.4m | 74.0m | ||||

## General and administrative expense | 73.6m | 120.6m | 138.4m | 137.2m | ||||

## Operating expense total | 145.7m | 233.3m | 234.6m | 213.5m | ||||

## EBIT | (22.2m) | (50.0m) | (75.1m) | (96.9m) | (145.7m) | (209.7m) | (187.5m) | (155.7m) |

| (867%) | (268%) | (187%) | |||||

## Interest expense | ||||||||

## Pre tax profit | (74.2m) | (98.9m) | (146.9m) | (232.6m) | (199.7m) | (177.9m) | ||

## Income tax expense | 139.0k | 193.0k | (1.8m) | 3.0k | (90.0k) | 5.2m | ||

## Net Income | (31.1m) | (48.1m) | (74.4m) | (99.1m) | (145.1m) | (232.6m) | (199.6m) | (183.1m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|

## Cash | 69.6m | 85.6m | 91.1m | 197.9m | 197.6m | 202.8m | 143.9m | 151.6m |

## Accounts Receivable | 399.0m | 2.7m | 38.4m | 56.0m | ||||

## Prepaid Expenses | 4.5m | 4.5m | 7.7m | 8.3m | ||||

## Inventories | 618.0k | 1.1m | 1.9m | 4.0m | 10.1m | 21.1m | 27.1m | |

## Current Assets | 70.3m | 141.0m | 138.4m | 237.7m | 254.1m | 220.2m | 376.3m | 331.8m |

## PP&E | 31.9m | 60.5m | 58.1m | 54.3m | ||||

## Total Assets | 70.5m | 161.1m | 159.1m | 248.3m | 290.3m | 285.0m | 452.6m | 402.0m |

## Accounts Payable | 3.5m | 551.0k | 551.0k | 551.0k | 6.2m | 12.4m | 12.8m | 8.8m |

## Short-term debt | 4.9m | |||||||

## Current Liabilities | 3.5m | 8.9m | 17.1m | 19.4m | 25.2m | 50.8m | 83.6m | 104.5m |

## Long-term debt | 12.1m | 220.6m | ||||||

## Total Debt | 12.1m | 225.5m | ||||||

## Total Liabilities | 142.9m | 154.7m | 57.2m | 285.7m | 378.1m | |||

## Common Stock | 37.0k | 45.0k | 46.0k | 47.0k | ||||

## Preferred Stock | ||||||||

## Additional Paid-in Capital | 162.0m | 171.3m | 236.5m | 422.0m | 597.3m | 924.2m | 1.1b | 1.1b |

## Retained Earnings | (143.2m) | (217.6m) | (316.6m) | (461.7m) | (696.4m) | (896.0m) | (1.1b) | |

## Total Equity | 67.0m | 18.8m | 105.3m | 135.6m | 227.8m | 167.0m | 24.0m | |

## Financial Leverage | 1.1 x | 8.5 x | 2.4 x | 2.1 x | 1.3 x | 2.7 x | 16.8 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|

## Net Income | (31.1m) | (48.1m) | (74.4m) | (99.1m) | (145.1m) | (232.6m) | (199.6m) | (183.1m) |

## Depreciation and Amortization | 64.0k | 73.0k | 252.0k | 970.0k | 1.4m | 13.0m | 34.2m | |

## Accounts Receivable | (2.7m) | (35.6m) | (17.7m) | |||||

## Inventories | (9.7m) | (10.3m) | (5.2m) | |||||

## Accounts Payable | 2.0m | 551.0k | 925.0k | 26.6m | 28.8m | 22.5m | ||

## Cash From Operating Activities | (16.4m) | (33.7m) | (55.7m) | (79.8m) | (93.2m) | (152.6m) | (150.4m) | (64.7m) |

## Purchases of PP&E | (16.0m) | (31.3m) | (10.0m) | (3.1m) | ||||

## Cash From Investing Activities | (63.0k) | (73.3m) | 9.4m | 18.1m | (42.8m) | 20.8m | (183.2m) | 73.2m |

## Long-term Borrowings | (8.3m) | |||||||

## Cash From Financing Activities | 83.2m | 123.0m | 51.8m | 168.6m | 135.6m | 137.0m | 274.8m | (859.0k) |

## Net Change in Cash | (376.0k) | 5.2m | (58.9m) | 7.6m | ||||

## Interest Paid | 2.2m | 2.2m | 2.2m | 1.8m | 6.5m | 5.0m | ||

## Income Taxes Paid | 600.0k | 1.8m | 5.0m |

USD | Q3, 2013 |
---|---|

## Financial Leverage | -0.1 x |